Protalix BioTherapeutics
PLX
PLX
45 hedge funds and large institutions have $120M invested in Protalix BioTherapeutics in 2014 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
25% less capital invested
Capital invested by funds: $160M → $120M (-$39.9M)
86% less call options, than puts
Call options by funds: $367K | Put options by funds: $2.7M
Holders
45
Holding in Top 10
1
Calls
$367K
Puts
$2.7M
Top Buyers
| 1 | +$1.92M | |
| 2 | +$411K | |
| 3 | +$303K | |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$278K |
| 5 |
SIM
Spark Investment Management
New York
|
+$169K |
Top Sellers
| 1 | -$6.08M | |
| 2 | -$2.72M | |
| 3 | -$1.08M | |
| 4 |
BCMU
BlueCrest Capital Management (UK)
St. Peter Port,
Guernsey
|
-$334K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$292K |